Lipopolysaccharide engineering in Neisseria meningitidis: structural analysis of different pentaacyl lipid A mutants and comparison of their modified agonist properties.
about
Outer membrane vesicles as platform vaccine technologyGlycoengineered Outer Membrane Vesicles: A Novel Platform for Bacterial VaccinesMeningococcal Outer Membrane Vesicle Composition-Dependent Activation of the Innate Immune Response.A Meningococcal Outer Membrane Vesicle Vaccine Incorporating Genetically Attenuated Endotoxin Dissociates Inflammation from Immunogenicity.Biosynthetically engineered lipopolysaccharide as vaccine adjuvant.The Neisseria meningitidis lpxL1 mutant induces less tissue factor expression and activity in primary human monocytes and monocyte-derived microvesicles than the wild type meningococcus.Modulating endotoxin activity by combinatorial bioengineering of meningococcal lipopolysaccharide.Whole-blood incubation with the Neisseria meningitidis lpxL1 mutant induces less pro-inflammatory cytokines than the wild type, and IL-10 reduces the MyD88-dependent cytokines.
P2860
Q26766539-30BB0900-F4DD-4369-9148-8D09E6D78B65Q36823959-E0472B05-8E94-4F7D-95ED-F14B67BD4F6DQ37287207-B42232A0-5FAB-4C44-A7E3-FFE9ED5466F7Q37483629-DD5370D3-B1F9-4F1B-9F80-8D93AF8D4C78Q38386726-04F001DA-3DF3-432D-97A6-4DE568DC0964Q39063955-46152CFD-E7A0-4CE7-A514-D659882D57BDQ40453387-56A35C2A-47B3-4239-897F-D83B7FC65240Q50126137-065CD91F-C5D1-4144-9596-FF927AAFC845
P2860
Lipopolysaccharide engineering in Neisseria meningitidis: structural analysis of different pentaacyl lipid A mutants and comparison of their modified agonist properties.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lipopolysaccharide engineering ...... r modified agonist properties.
@en
Lipopolysaccharide engineering ...... r modified agonist properties.
@nl
type
label
Lipopolysaccharide engineering ...... r modified agonist properties.
@en
Lipopolysaccharide engineering ...... r modified agonist properties.
@nl
prefLabel
Lipopolysaccharide engineering ...... r modified agonist properties.
@en
Lipopolysaccharide engineering ...... r modified agonist properties.
@nl
P2093
P2860
P356
P1476
Lipopolysaccharide engineering ...... r modified agonist properties.
@en
P2093
Elder Pupo
Hendrik-Jan Hamstra
Hugo Meiring
Peter van der Ley
P2860
P304
P356
10.1074/JBC.M114.554345
P407
P577
2014-02-03T00:00:00Z